Bora Pharmaceuticals & Celltrion Partner to Expand OSD Capabilities in APAC Market

Bora Pharmaceuticals Co., Ltd. and Celltrion Asia Pacific Pte., Ltd. recently announced their partnership to contract manufacture and commercialize a range of oral dosage form drugs (OSD) across the APAC region.

The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, which is one of the largest US FDA- and MHRA-approved pharmaceutical production facilities in Taiwan. The site has an outstanding compliance record across global regulatory authorities.

The manufactured batches will be used to support Celltrion’s regulatory filings for approval in seven countries, and Bora will further support Celltrion to commercialize the products immediately upon approval by utilizing its cutting-edge manufacturing capabilities in complex oral dosage form and superior total-solution services.

Bobby Sheng, CEO and Chairman of Bora, said “We are extremely excited about this new partnership with Celltrion. As a trusted global partner, we look forward to serving our customers with the best technical and quality resources and supporting our partners to expand into various markets around the world.”

Bora Pharmaceuticals is a premier international cGMP CDMO specializing in complex oral solid dosage, non-sterile liquids, sterile and non-sterile ophthalmics, nasal sprays, and semi-solids pharmaceutical products for Clinical through Commercial manufacturing and packaging and clinical manufacturing of biologics drug substance.  Bora owns and operates seven state-of-the-art CGMP manufacturing facilities (Taiwan and Canada) built to the highest international standards for development manufacturing, packaging, and analytical testing. Our TAA-compliant sites deliver to more than 100 markets around the world. For more information visit www.boracorpcdmo.com

Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, and manufacturing innovative therapeutics that improve people’s lives worldwide. Our solutions include world-class monoclonal antibody biosimilars, such as Remsima, Truxima, and Herzuma, providing broader patient access globally. We have also received US FDA and EMA approval for Vegzelma, and EMA approval for Yuflyma and Remsima SC.

At Celltrion, we pursue sustainable growth by leveraging our experience and assets in the successful biosimilar business to develop new medicines and healthcare platform technologies. We work with a sense of duty to advance patients’ wellness and provide them with enhanced access to reliable healthcare. To accomplish this, we adhere to strong internal ethical standards in our daily operations. For more information, visit www.celltrion.com.